Deer­field takes trans­la­tion­al part­ner­ship mod­el to Har­vard with $100M deal

In an in­creas­ing­ly gen­er­ous ef­fort to bridge some of Amer­i­ca’s best bio­med­ical re­search with the com­mer­cial world, Deer­field has com­mit­ted $100 mil­lion to a new trans­la­tion­al re­search al­liance with Har­vard Uni­ver­si­ty.

Through a com­pa­ny dubbed Lab1636, Deer­field will fund a num­ber of R&D projects that bol­ster drug dis­cov­ery and de­vel­op­ment, for ex­am­ple stud­ies to ex­pli­cate the bi­ol­o­gy of dis­ease, val­i­date ther­a­peu­tic tar­gets, or achieve IND-en­abling proof-of-con­cepts. In ad­di­tion, the in­vest­ment firm will help uni­ver­si­ty re­searchers li­aise with out­side com­pa­nies for li­cens­ing deals, as well as nur­ture new star­tups com­ing out of the uni­ver­si­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.